Comparative efficacy of two next-generation Rift Valley fever vaccines

Vaccine

Volumn 32, Issue 39, 2014, Pages 4901-4908

  Kortekaas, J ^a   Oreshkova, N ^a,b   van Keulen, L ^a   Kant, J ^a   Bosch, B J ^b   Bouloy, M ^c   Moulin, V ^d   Goovaerts, D ^d,e   Moormann, R J M ^a,b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c INSTITUT PASTEUR   (France)

^d INTERVET INTERNATIONAL BV   (Netherlands)

^e DGVAC Consultancy ^*  (Belgium)

Author keywords

Clone 13; Comparative; Nonspreading; NSR Gn; R566; Replicon; Rift Valley fever virus; Sheep; Vaccine

Indexed keywords

CLONE 13 VACCINE; R 566; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CLONE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEVER; GENETIC REASSORTMENT; LAMB; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVERSE GENETICS; RIFT VALLEY FEVER; VACCINATION; VIREMIA; ANIMAL; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; RANDOMIZATION; RIFT VALLEY FEVER VIRUS; SERODIAGNOSIS; SHEEP; SHEEP DISEASES; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; NEUTRALIZATION TESTS; RANDOM ALLOCATION; REASSORTANT VIRUSES; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; RNA, VIRAL; SHEEP; SHEEP DISEASES; VACCINES, ATTENUATED; VIRAL VACCINES; VIREMIA;

EID: 84906093045     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.037     Document Type: Article

References (37)

1. Bird B.H., Nichol S.T. Breaking the chain: Rift Valley fever virus control via livestock vaccination. Curr Opin Virol 2012, 2:315-323.
2. Smithburn K.C. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 1949, 30:1-16.
3. Kamal S.A. Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J 2009, 6:94.
4. Botros B., Omar A., Elian K., Mohamed G., Soliman A., Salib A., et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J Med Virol 2006, 78:787-791.
5. Caplen H., Peters C.J., Bishop D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 1985, 66:2271-2277.
6. Saluzzo J.F., Smith J.F. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine. Vaccine 1990, 8:369-375.
7. Morrill J.C., Mebus C.A., Peters C.J. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 1997, 58:1110-1114.
8. Morrill J.C., Mebus C.A., Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 1997, 58:1104-1109.
9. Morrill J.C., Laughlin R.C., Lokugamage N., Pugh R., Sbrana E., Weise W.J., et al. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine 2013, 31:559-565.
10. Morrill J.C., Jennings G.B., Caplen H., Turell M.J., Johnson A.J., Peters C.J. Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res 1987, 48:1042-1047.
11. Morrill J.C., Carpenter L., Taylor D., Ramsburg H.H., Quance J., Peters C.J. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 1991, 9:35-41.
12. Morrill J.C., Laughlin R.C., Lokugamage N., Wu J., Pugh R., Kanani P., et al. Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. Vaccine 2013, 31:4988-4994.
13. Muller R., Saluzzo J.F., Lopez N., Dreier T., Turell M., Smith J., et al. Characterization of Clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995, 53:405-411.
14. Billecocq A., Spiegel M., Vialat P., Kohl A., Weber F., Bouloy M., et al. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol 2004, 78:9798-9806.
15. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 2001, 75:1371-1377.
16. Le May N., Mansuroglu Z., Leger P., Josse T., Blot G., Billecocq A., et al. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog 2008, 4:e13.
17. Le May N., Dubaele S., Proietti De Santis L., Billecocq A., Bouloy M., Egly J.M. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 2004, 116:541-550.
18. Kalveram B., Lihoradova O., Ikegami T. NSs protein of rift valley fever virus promotes posttranslational downregulation of the TFIIH subunit p62. J Virol 2011, 85:6234-6243.
19. Ikegami T., Narayanan K., Won S., Kamitani W., Peters C.J., Makino S. Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR. Ann N Y Acad Sci 2009, 1171(Suppl. 1):E75-E85.
20. Habjan M., Pichlmair A., Elliott R.M., Overby A.K., Glatter T., Gstaiger M., et al. NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol 2009, 83:4365-4375.
21. Benferhat R., Josse T., Albaud B., Gentien D., Mansuroglu Z., Marcato V., et al. Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome. J Virol 2012, 86:11333-11344.
22. Mansuroglu Z., Josse T., Gilleron J., Billecocq A., Leger P., Bouloy M., et al. Nonstructural NSs protein of rift valley fever virus interacts with pericentromeric DNA sequences of the host cell, inducing chromosome cohesion and segregation defects. J Virol 2010, 84:928-939.
23. Austin D., Baer A., Lundberg L., Shafagati N., Schoonmaker A., Narayanan A., et al. p53 Activation following Rift Valley fever virus infection contributes to cell death and viral production. PLoS ONE 2012, 7:e36327.
24. Baer A., Austin D., Narayanan A., Popova T., Kainulainen M., Bailey C., et al. Induction of DNA damage signaling upon Rift Valley fever virus infection results in cell cycle arrest and increased viral replication. J Biol Chem 2012, 287:7399-7410.
25. Dungu B., Louw I., Lubisi A., Hunter P., von Teichman B.F., Bouloy M. Evaluation of the efficacy and safety of the Rift Valley fever Clone 13 vaccine in sheep. Vaccine 2010, 28:4581-4587.
26. von Teichman B., Engelbrecht A., Zulu G., Dungu B., Pardini A., Bouloy M. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 2011, 29:5771-5777.
27. Bouloy M., Flick R. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antiviral Res 2009, 84:101-118.
28. Oreshkova N., van Keulen L., Kant J., Moormann R.J., Kortekaas J. A single vaccination with an improved nonspreading rift valley Fever virus vaccine provides sterile immunity in lambs. PLOS ONE 2013, 8:e77461.
29. Vialat P., Muller R., Vu T.H., Prehaud C., Bouloy M. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res 1997, 52:43-50.
30. Vialat P., Billecocq A., Kohl A., Bouloy M. The S segment of rift valley fever phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice. J Virol 2000, 74:1538-1543.
31. Billecocq A., Vialat P., Bouloy M. Persistent infection of mammalian cells by Rift Valley fever virus. J Gen Virol 1996, 77:3053-3062.
32. Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharm 1931, 162:480-483.
33. Spearman C. The method of right and wrong cases (constant stimuli) without Gauss's formulae. Br J Psych 1908, 2:227-242.
34. Kortekaas J., Oreshkova N., Cobos-Jimenez V., Vloet R.P., Potgieter C.A., Moormann R.J. Creation of a nonspreading Rift Valley fever virus. J Virol 2011, 85:12622-12630.
35. Kortekaas J., Antonis A.F.G., Kant J., Vloet R.P.M., Vogel A., Oreshkova N., et al. Efficacy of three candidate Rift Valley fever vaccines in sheep. Vaccine 2012, 30:3423-3429.
36. Drosten C., Gottig S., Schilling S., Asper M., Panning M., Schmitz H., et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 2002, 40:2323-2330.
37. Keegan K., Collett M.S. Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. J Virol 1986, 58:263-270.